Grail Files for IPO After $1 Billion Funding Round Led by Tencent to Advance Ultra-Early Cancer Detection via Genomic Sequencing

Securing $1 billion in funding within just one year of its founding, GRAIL would undoubtedly have become a household name if it were in the internet sector. However, GRAIL remains relatively unknown because it operates in the field of ultra-early cancer screening, targeting asymptomatic or healthy individuals. GRAIL employs gene sequencing technology, tackling a highly cutting-edge yet challenging endeavor.

Leiphone.com (WeChat Official Account: Leiphone) reported that on March 1, GRAIL announced it had secured $900 million in Series B financing, co-led by ARCH Venture Partners and Johnson & Johnson Innovation. Other investors participating in the round included Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, and Tencent.

GRAIL was founded in January 2016 by the global sequencing giant Illumina, securing $100 million in initial investment from ARCH Venture Partners, Bill Gates, Jeff Bezos, and Google Ventures.

Why Do Top Investors Value Grail So Highly? What Technologies Does It Use, and What Changes Could It Bring to Human Health and Healthcare? Leiphone(WeChat Official Account: Leifeng.com)Compiled based on publicly available information.

Ultra-Early Cancer Screening: “Finding a Needle in a Haystack”

Cancer is a nightmare for humanity, particularly in its middle and late stages. Often, by the time patients experience physical discomfort and seek medical examination, the disease has already progressed to an advanced stage, making it difficult to cure. Research indicates that the survival rate for patients with early-stage cancer is five times higher than that for those with middle- or late-stage cancer. Early detection represents the most effective and cost-efficient approach to maximizing the likelihood of a cure.

However, early screening is not straightforward, as the etiology of cancer is highly complex. Current clinical methods, including X-ray, endoscopy, ultrasound, blood biochemistry, and cytological diagnosis, are generally targeted at individuals who already present with overt symptoms. For a significant proportion of patients in the very early stages, these methods fail to detect abnormalities.

GRAIL utilizes gene sequencing technology (its parent company, Illumina, originally built its business on gene sequencing). The fundamental principle is that when tumor cells in cancer patients rupture, they release circulating tumor DNA (ctDNA) into the bloodstream. By detecting this DNA information and comparing it with known tumor mutation gene sequences, cancer can be detected at a very early stage.

It may sound straightforward, but the biggest challenge is that ctDNA levels in the blood are extremely low. Furthermore, as previously mentioned, the etiology of cancer is highly complex, making it difficult to compare and identify cancer-specific genomic sequences. GRAIL states on its official website that it has identified millions of unique genomic sequences for cancer diagnosis, underscoring the complexity of the issue.

“Finding an effective method for diagnosing early-stage cancer is akin to ‘finding a needle in a haystack,’” said GRAIL.

GRAIL's Advantage: Expanding the Depth and Breadth of Genomic Sequencing with Data Science

Much like big data, although the pathogenesis of cancer remains not fully understood by humans, the ctDNA information released by tumor cells into the human circulatory system can be monitored and analyzed. GRAIL and its investors believe they possess a unique advantage in this regard: the application of modern data science has enabled them to achieve unprecedented depth and breadth in gene sequencing.

GRAIL aims to acquire high-quality data from laboratories, clinics, and hospitals, and transform it into insights that can guide clinical practice. GRAIL revealed that the volume of data obtained from each patient is as high as 1 TB, representing an unprecedented scale in modern clinical medicine.

To “tackle” data of this scale, GRAIL has applied the latest advances in data science, including machine learning techniques such as hierarchical neural networks, with the aim of appropriately stratifying patients based on their clinical presentation, cancer type, and disease severity.

Next, GRAIL will conduct large-scale clinical studies and trials, enrolling as many cancer patients and healthy individuals as possible to enhance the accuracy of its sequencing technology.

Team: An all-star lineup comprising a Google VP and MDs

GRAIL’s involvement in genetic engineering, healthcare, and data science—each of which demands substantial investment and top-tier talent—also constitutes its competitive advantage. Otherwise, how could it have secured $100 million in financing immediately upon its establishment?

Jeff Huber is the CEO of GRAIL. He graduated from the University of Illinois with a degree in Computer Engineering and earned a master’s degree from Harvard University. Starting in 2003, he served as a Vice President at Google, where he successively led Google Ads (2003–2011), Google Apps (2005–2010), and Google Maps (2011–2013). Additionally, he serves on the board of directors of electronic arts giant EA. From 2014 to 2016, he also served on the board of directors of Illumina, GRAIL’s parent company. Such a professional background has well positioned him to help GRAIL attract top-tier data scientists and MDs from Silicon Valley.

（Jeff Huber）

Jeff Huber’s willingness to serve as CEO of GRAIL is largely driven by his personal experiences. His beloved wife, Laura, was diagnosed with colon cancer; despite exhausting every available treatment option, her disease had already progressed to an advanced stage, and she ultimately passed away from the illness. This profound loss deeply affected Huber, and after his wife’s death, he decided to lead this company dedicated to early cancer screening.

Tencent also emerged as an investor in GRAIL’s latest funding round. In fact, Tencent and its founder Ma Huateng have long maintained a focus on the healthcare sector. According to a compilation by Huxiu.com, since 2012, Tencent has successively invested in domestic companies such as Linjia Yisheng (Family Doctor), PICOOC, DXY.cn, WeDoctor (Guahaowang), Zhuojian Technology, and Medlinker, as well as international firms including the Indian medical information service provider Practo, smart medical hardware manufacturers Clinicloud and Scanadu, among others.

Original article by Leiphone; unauthorized reproduction is prohibited. For details, seeReprint Guidelines。